Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation.

Détails

ID Serval
serval:BIB_6D0849323A76
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation.
Périodique
Oncotarget
Auteur⸱e⸱s
Hocquelet A., Seror O., Blanc J.F., Frulio N., Salut C., Nault J.C., Trillaud H.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Statut éditorial
Publié
Date de publication
09/05/2017
Peer-reviewed
Oui
Volume
8
Numéro
19
Pages
32190-32200
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To compare treatment failure and survival associated with ultrasound-guided radiofrequency ablation (RFA) and trans-arterial chemoembolization (TACE) for early-stage HCC in Child-Pugh A cirrhosis patients.
122 cirrhotic patients (RFA: 61; TACE: 61) were well matched according to cirrhosis severity; tumor size and serum alpha-fetoprotein. TACE was performed in case of inconspicuous nodule on US or nodule with "at risk location". Treatment failure was defined as local tumor progression (LTP) and primary treatment failure (failing to obtain complete response after two treatment session). Treatment failure and overall survival (OS) were compared after coarsened exact matching. Cox proportional model to assess independent predictive factors was performed.
No significant difference was seen for baseline characteristics between the two groups. Mean tumor size was 3cm in both group with 41% HCC>3cm. Treatment failure rates after TACE was 42.6% (14 primary treatment failures and 12 LTP) and 9.8% after RFA (no primary treatment failure and 6 LTP) P < 0.001. TACE was the only predictive factor of treatment failure (Hazard ratio: 5.573). The 4-years OS after RFA and TACE were 54.1% and 31.5% (P = 0.042), respectively.
For Child-Pugh A patients with early-stage HCC, alternative treatment as supra-selective TACE to RFA regarded as too challenging using common US guidance decrease significantly the local tumor control and overall survival. Efforts to improve feasibility of RFA especially for inconspicuous target have to be made.

Mots-clé
carcinoma, hepatocellular, chemoembolization, therapeutic, radiofrequency ablation
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/10/2017 14:53
Dernière modification de la notice
20/08/2019 15:26
Données d'usage